Related Experiment Video

Updated: Sep 3, 2025

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

8.8K

Molecular Characterization of the Response to Conventional Chemotherapeutics in Pro-B-ALL Cell Lines in Terms of

Yvonne Saara Gladbach1,2,3, Lisa-Madeleine Sklarz4, Catrin Roolf4

  • 1Institute for Biostatistics and Informatics in Medicine and Ageing Research (IBIMA), Rostock University Medical Center, 18057 Rostock, Germany.

Genes
|July 27, 2022
PubMed

Insights

Understanding cancer relapse mechanisms is key. This study reveals crucial genes and miRNAs involved in drug resistance and sensitivity in MLL-rearranged B-cell acute lymphoblastic leukemia, guiding future therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genomics

Background:

  • Optimizing chemotherapy sequencing for reduced tumor burden and improved efficacy remains challenging.
  • Understanding molecular mechanisms of drug action and tumor relapse is crucial for clinical treatment optimization and reducing side effects.

Purpose of the Study:

  • To investigate dynamic regulatory reprogramming leading to tumor relapse in MLL-rearranged pro-B-cell acute lymphoblastic leukemia (B-ALL) cells.
  • To identify key driver genes and miRNAs controlling relapse mechanisms following dexamethasone (Dexa) and cytarabine (AraC) treatment.

Main Methods:

  • Integrative molecular analysis of whole transcriptome profiles from B-ALL cells treated with Dexa and AraC.
  • Network-based approach incorporating miRNA regulation to unravel gene and miRNA interactions.

Main Results:

  • Identified crucial regulatory genes associated with dexamethasone resistance.
  • Uncovered specific miRNAs linked to chemotherapy sensitivity in relapsed B-ALL.
  • Provided insights into molecular mechanisms driving treatment resistance and relapse.

Conclusions:

  • Specific genes and miRNAs play critical roles in dexamethasone resistance and chemosensitivity in MLL-rearranged B-ALL.
  • These identified molecular players warrant further investigation in preclinical models to elucidate relapse processes.
  • Findings contribute to a better understanding of therapeutic strategies for B-ALL relapse.
Keywords:
acute lymphoblastic leukemiacytarabinecytostaticsdexamethasonedrug responsetumor relapse

More Related Videos

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.7K
Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

13.9K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.0K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.5K